source
- Merck signs up to $2.13 billion deal with SciBrunch for preclinical KRAS inhibitor SPR2015Merck announced it has completed a deal with Chinese biotech SciBrunch Therapeutics, paying $400 million upfront for exclusive global rights to develop, manufacture and commercialize SciBrunch’s pr…
- Merck and Daiichi Sankyo pull accelerated approval request for lung cancer ADCMerck and Daiichi Sankyo have voluntarily withdrawn their application for accelerated approval of the antibody-drug conjugate ifinatamab deruxtecan. The FDA indicated that the data package did not…